Additional file 1. JAVELIN Solid Tumor: Study Profile, Urothelial Carcinoma Cohorts

- 329 patients assessed for eligibility
  - 80 excluded
    - 67 did not meet eligibility criteria
    - 6 withdrew consent
    - 6 due to other reasons
    - 1 not reported

- 249 patients enrolled and treated with ≥1 dose
  - 12 treatment ongoing
  - 237 discontinued treatment
    - 155 due to disease progression
    - 39 due to an adverse event
    - 13 withdrew consent
    - 13 due to death
    - 2 due to protocol non-compliance
    - 15 due to other reasons

- 249 patients analysed
  - 249 included in the safety analysis set
  - 242 excluding those who are platinum-naïve
  - 161 excluding those who are platinum-naïve with ≥2 years of follow-up